Multidisciplinary Approaches to the Management of Atopic Dermatitis - Episode 8
Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Video content above is prompted by the following:
4. How do the treatment options evolve as a child ages?
a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
5. How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
a. Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.
